Tag: report

Embracing Innovation in Tenosynovitis Treatment: The global Tenosynovitis market is advancing rapidly, driven by the rising prevalence of inflammatory diseases like rheumatoid arthritis. As aging populations increase, demand grows for effective treatments to manage this tendon sheath inflammation. Biologic and targeted therapies, including TNF and IL-6 inhibitors, are at the forefront, alongside non-invasive options like PRP therapy. Leading companies such as Pfizer and AbbVie are fueling innovation with personalized medicine, addressing challenges of early diagnosis and treatment accessibility. Discover the future of tenosynovitis care and market trends shaping this evolving landscape.

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it has amended its loan facility (the “Amended Loan Agreement”) with funds and accounts managed by BlackRock (the “Lender”).

AS Tallinna Vesi’s sales in the second quarter were €19.4 million, the increase was mainly driven by the sales of construction services. 

New York, NY, July 31, 2025 (GLOBE NEWSWIRE) -- The Ether Machine, the ether generation company, announced yesterday that The Ether Reserve LLC has purchased nearly 15,000 ETH at $3,809.97 USD for a total of $56,900,000.01 USD as part of The Ether Machine’s long-term accumulation strategy. This brings total ETH purchased and committed to 334,757 with up to $407,000,000 of USD remaining for additional ETH purchases.

LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months.